1 | F 18 T807 | - | - | - | - | 2件: 2 2, 127 |
2 | F-18 | - | - | - | - | 2件: 5 5, 127 |
3 | F-18 3F4AP | - | - | - | - | 1件: 13 13 |
4 | F-18 AV 1451 | - | - | - | - | 2件: 5 5, 127 |
5 | F-18 FDG | - | - | - | - | 1件: 127 127 |
6 | F-18 FEDAA1106 (BAY85-8101) | - | - | - | - | 1件: 13 13 |
7 | F-18 FPCIT | - | - | - | - | 1件: 6 6 |
8 | F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid) | - | - | - | - | 1件: 299 299 |
9 | F13CD | - | - | - | - | 1件: 288 288 |
10 | F18CETO | - | - | - | - | 1件: 75 75 |
11 | F8IL10 | - | - | - | - | 2件: 46 46, 97 |
12 | F8VR | - | - | - | - | 1件: 288 288 |
13 | FAB122 | - | - | - | - | 1件: 2 2 |
14 | FABRAZYME | 1件: Agalsidase beta Agalsidase beta | 1件: D03228
D03228
| 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 |
15 | Fabrazyme (agalsidase beta) | 1件: Agalsidase beta Agalsidase beta | 1件: D03228
D03228
| 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 |
16 | Fabrazyme (agalsidase beta) 1 mg/kg | 1件: Agalsidase beta Agalsidase beta | 1件: D03228
D03228
| 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 |
17 | FABRAZYME - 35 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE ENDOVENOSA 1 FLACONCINO | 1件: Agalsidase beta Agalsidase beta | 1件: D03228
D03228
| 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 |
18 | Fabrazyme 35 mg | 1件: Agalsidase beta Agalsidase beta | 1件: D03228
D03228
| 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 |
19 | Fabrazyme 5 mg | 1件: Agalsidase beta Agalsidase beta | 1件: D03228
D03228
| 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 |
20 | FACS analyses | - | - | - | - | 1件: 65 65 |
21 | FACTANE 200 IU/ml | - | - | - | - | 1件: 288 288 |
22 | Factor VIII | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 |
23 | Factor VIII concentrate | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 |
24 | Factor von Willebrand | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 |
25 | FACTOR X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 |
26 | Factor XIIa antagonist monoclonal antibody | - | - | - | - | 1件: 85 85 |
27 | Factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 3件: 51 51, 97, 288 |
28 | Factor XIII Concentrate (Human) | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 |
29 | Factor XIII Concentrate (Human), Pasteurized | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 |
30 | Faecal matter | - | - | - | - | 1件: 97 97 |
31 | Faecal Microbiota Transplant | - | - | - | - | 1件: 97 97 |
32 | Faecal microbiota transplantation | - | - | - | - | 5件: 46 46, 84, 96, 97, 271 |
33 | Faecal sampling | - | - | - | - | 1件: 46 46 |
34 | FAM Therapy | - | - | - | - | 1件: 228 228 |
35 | FamC-1 | - | - | - | - | 1件: 2 2 |
36 | Famciclovir | 1件: Famciclovir Famciclovir | 1件: D00317
D00317
| - | - | 2件: 11 11, 13 |
37 | FAMOTIDINA | 1件: Famotidine Famotidine | 1件: D00318
D00318
| 1件: HRH2 HRH2 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬 | 1件: 61 61 |
38 | Famotidine | 1件: Famotidine Famotidine | 1件: D00318
D00318
| 1件: HRH2 HRH2 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬 | 5件: 6 6, 46, 86, 98, 107 |
39 | Famotidine 20 MG | 1件: Famotidine Famotidine | 1件: D00318
D00318
| 1件: HRH2 HRH2 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬 | 1件: 86 86 |
40 | FAMPRIDINA | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
41 | FAMPRIDINE | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 13 13, 14 |
42 | Fampridine SR | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
43 | Fampridine-SR | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
44 | Fampridine-SR b.i.d. (Twice Daily) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
45 | FAMPYRA | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 13 13, 14 |
46 | FAMPYRA - 10 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - FLACONE (HDPE) 56 COMPRESSE (4 FLACONI DA 14) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
47 | Fampyra 10 mg prolonged-release tablets | 2件: Dalfampridine Dalfampridine, Manganese citrate | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
48 | Fampyra 10mg prolonged release tablets | 2件: Dalfampridine Dalfampridine, Manganese citrate | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
49 | Fang yi qing feng shi granule | - | - | - | - | 1件: 46 46 |
50 | FANG(30) | - | - | - | - | 1件: 46 46 |
51 | Fanhdi | - | - | - | - | 1件: 288 288 |
52 | FANHDI 100 UI | - | - | - | - | 1件: 288 288 |
53 | Fanhdi 100 UI FVIII-120 UI FVW | - | - | - | - | 1件: 288 288 |
54 | FANHDI 25 UI | - | - | - | - | 1件: 288 288 |
55 | Fanhdi 25 UI FVIII-30 UI FVW | - | - | - | - | 1件: 288 288 |
56 | FANHDI 250UI*1F 250UI+F 10ML | - | - | - | - | 1件: 288 288 |
57 | FANHDI 50 UI | - | - | - | - | 1件: 288 288 |
58 | Fanhdi 50 UI FVIII-60 UI FVW | - | - | - | - | 1件: 288 288 |
59 | FANHDI*INF FL 250UI+SIR SOLV+S | - | - | - | - | 1件: 288 288 |
60 | FANHDI*INF FL 500UI+SIR SOLV+S | - | - | - | - | 1件: 288 288 |
61 | FANHDI*INF FL1000UI+SIR SOLV+S | - | - | - | - | 1件: 288 288 |
62 | FANHDI*INF FL250UI+SIR SOLV+S | - | - | - | - | 1件: 288 288 |
63 | Fansidar (pyrimethamine and sulfadoxine) | 2件: Pyrimethamine Pyrimethamine, Sulfadoxine | 2件: D00488
D00488
,
D00580
| - | - | 1件: 65 65 |
64 | Fasenra | 1件: Benralizumab Benralizumab | 1件: D09874
D09874
| 1件: IL5RA IL5RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 5件: 44 44, 45, 98, 162, 299 |
65 | Faslodex | 1件: Fulvestrant Fulvestrant | 1件: D01161
D01161
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 49 49 |
66 | Fasudil | 1件: Fasudil Fasudil | 1件: D07941
D07941
| 2件: ROCK1 ROCK1, ROCK2 💬 | 23件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 2 2, 5, 7, 51 |
67 | Fasudil (WP-0512) | 1件: Fasudil Fasudil | 1件: D07941
D07941
| 2件: ROCK1 ROCK1, ROCK2 💬 | 23件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 |
68 | FASUDIL HYDROCHLORIDE | 1件: Fasudil Fasudil | 1件: D07941
D07941
| 2件: ROCK1 ROCK1, ROCK2 💬 | 23件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 |
69 | Fat diet | - | - | - | - | 1件: 78 78 |
70 | Fatigue | - | - | - | - | 1件: 13 13 |
71 | FAXE Kondi | - | - | - | - | 1件: 257 257 |
72 | Faxe Kondi Free | - | - | - | - | 1件: 257 257 |
73 | Fazisiran Injection | - | - | - | - | 1件: 231 231 |
74 | FB-101 | - | - | - | - | 1件: 6 6 |
75 | FB704A | - | - | - | - | 1件: 46 46 |
76 | FBL-MTX | - | - | - | - | 1件: 46 46 |
77 | FBS0701 | - | - | - | - | 1件: 284 284 |
78 | FBS0701 CAPSULE | - | - | - | - | 1件: 284 284 |
79 | FBS0701/SSP004184 | - | - | - | - | 1件: 284 284 |
80 | FBX-101 | - | - | - | - | 1件: 19 19 |
81 | Fc- and CDR-modified humanised monoclonal antibody against C5 | - | - | - | - | 3件: 11 11, 62, 109 |
82 | FCM | - | - | - | - | 1件: 222 222 |
83 | FCR001 | - | - | - | - | 1件: 51 51 |
84 | FCX-007 | - | - | - | - | 1件: 36 36 |
85 | FCX-013 | - | - | - | - | 1件: 51 51 |
86 | FDC macitentan/tadalafil | 2件: Macitentan Macitentan, Tadalafil | 2件: D02008
D02008
,
D10135
| 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
87 | FDG | - | - | - | - | 1件: 84 84 |
88 | FDL169 | 1件: FDL169 FDL169 | - | - | - | 1件: 299 299 |
89 | FDL176 | - | - | - | - | 1件: 299 299 |
90 | FDL176 & FDL169 coadministration | 1件: FDL169 FDL169 | - | - | - | 1件: 299 299 |
91 | FE 992097 | - | - | - | - | 1件: 193 193 |
92 | FE 999301 | - | - | - | - | 2件: 96 96, 97 |
93 | Feburane | - | - | - | - | 1件: 21 21 |
94 | Febuxostat | 1件: Febuxostat Febuxostat | 1件: D01206
D01206
| 1件: XDH XDH 💬 | 6件: Caffeine metabolism Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Peroxisome, Purine metabolism 💬 | 3件: 2 2, 6, 13 |
95 | Fecal Microbial transplant | - | - | - | - | 2件: 96 96, 97 |
96 | Fecal microbial transplant (FMT) | - | - | - | - | 1件: 13 13 |
97 | Fecal Microbial Transplantation | - | - | - | - | 2件: 96 96, 97 |
98 | Fecal Microbial Transplants | - | - | - | - | 1件: 13 13 |
99 | Fecal microbiota | - | - | - | - | 3件: 13 13, 96, 97 |
100 | Fecal microbiota capsule | - | - | - | - | 1件: 97 97 |
101 | Fecal Microbiota Enema | - | - | - | - | 1件: 97 97 |
102 | Fecal Microbiota Transplant | - | - | - | - | 2件: 96 96, 97 |
103 | Fecal Microbiota Transplant (FMT) | - | - | - | - | 2件: 96 96, 97 |
104 | Fecal microbiota transplantation | - | - | - | - | 5件: 2 2, 66, 94, 96, 97 |
105 | Fecal Microbiota Transplantation (FMT) | - | - | - | - | 2件: 96 96, 97 |
106 | Fecal Microbiota Transplantation (FMT), OpenBiome | - | - | - | - | 1件: 97 97 |
107 | Fecal Microbiota Transplantation by Intra-rectal enemas | - | - | - | - | 1件: 97 97 |
108 | Fecal Microbiota Transplantation by Stool capsules | - | - | - | - | 1件: 97 97 |
109 | Fecal transplantation | - | - | - | - | 1件: 97 97 |
110 | Felzartamab | 1件: Felzartamab Felzartamab | - | - | - | 2件: 66 66, 222 |
111 | Femoston 1/10 | - | - | - | - | 1件: 13 13 |
112 | Femoston 2/10 | - | - | - | - | 1件: 13 13 |
113 | Fendrix | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 |
114 | Fendrix suspension for injection | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 |
115 | Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed). | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 |
116 | FENEBRUTINIB | 1件: Fenebrutinib Fenebrutinib | 1件: D11457
D11457
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 13 13 |
117 | Fenfluramina | 1件: Fenfluramine Fenfluramine | 1件: D07945
D07945
| 5件: HTR1D HTR1D, HTR2A, HTR2C, SIGMAR1, SLC6A4 💬 | 10件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, cAMP signaling pathway 💬 | 2件: 140 140, 144 |
118 | Fenfluramina Cloridrato | 1件: Fenfluramine Fenfluramine | 1件: D07945
D07945
| 5件: HTR1D HTR1D, HTR2A, HTR2C, SIGMAR1, SLC6A4 💬 | 10件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, cAMP signaling pathway 💬 | 2件: 140 140, 144 |
119 | FENFLURAMINE | 1件: Fenfluramine Fenfluramine | 1件: D07945
D07945
| 5件: HTR1D HTR1D, HTR2A, HTR2C, SIGMAR1, SLC6A4 💬 | 10件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, cAMP signaling pathway 💬 | 4件: 140 140, 144, 145, 149 |
120 | Fenfluramine HCl, DL-Fenfluramine, (±)-Fenfluramine | 1件: Fenfluramine Fenfluramine | 1件: D07945
D07945
| 5件: HTR1D HTR1D, HTR2A, HTR2C, SIGMAR1, SLC6A4 💬 | 10件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, cAMP signaling pathway 💬 | 1件: 144 144 |
121 | FENFLURAMINE HYDROCHLORIDE | 1件: Fenfluramine Fenfluramine | 1件: D07945
D07945
| 5件: HTR1D HTR1D, HTR2A, HTR2C, SIGMAR1, SLC6A4 💬 | 10件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, cAMP signaling pathway 💬 | 2件: 140 140, 144 |
122 | FENFLURAMINE HYDROCHLORIDE (colorless) | 1件: Fenfluramine Fenfluramine | 1件: D07945
D07945
| 5件: HTR1D HTR1D, HTR2A, HTR2C, SIGMAR1, SLC6A4 💬 | 10件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, cAMP signaling pathway 💬 | 2件: 140 140, 144 |
123 | FENFLURAMINE HYDROCHLORIDE (red) | 1件: Fenfluramine Fenfluramine | 1件: D07945
D07945
| 5件: HTR1D HTR1D, HTR2A, HTR2C, SIGMAR1, SLC6A4 💬 | 10件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle, Taste transduction, cAMP signaling pathway 💬 | 1件: 140 140 |
124 | Fengshigutong Capsule | - | - | - | - | 1件: 271 271 |
125 | Fengshigutong Capsule plus Imrecoxib | 1件: Imrecoxib Imrecoxib | - | - | - | 1件: 271 271 |
126 | Fenilbutirato | - | - | - | - | 1件: 2 2 |
127 | Fenofibrate | 1件: Fenofibrate Fenofibrate | 1件: D00565
D00565
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 6件: 8 8, 79, 93, 94, 97, 265 |
128 | Fenofibrate 160mg | 1件: Fenofibrate Fenofibrate | 1件: D00565
D00565
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 97 97 |
129 | Fenofibrate 200mg | 1件: Fenofibrate Fenofibrate | 1件: D00565
D00565
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
130 | Fenofibrate Combined With Ursodeoxycholic Acid | 2件: Fenofibrate Fenofibrate, Ursodeoxycholic acid | 2件: D00565
D00565
,
D00734
| 2件: NR1H4 NR1H4, PPARA 💬 | 11件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
131 | Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) | 1件: Fenofibrate Fenofibrate | 1件: D00565
D00565
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
132 | Fenretinide | 1件: Fenretinide Fenretinide | 1件: D04162
D04162
| 2件: RARA RARA, RARB 💬 | 8件: Acute myeloid leukemia Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 1件: 299 299 |
133 | Fentanyl | 1件: Fentanyl Fentanyl | 1件: D00320
D00320
| 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 3件: 46 46, 70, 215 |
134 | Fentanyl (High Dose) | 1件: Fentanyl Fentanyl | 1件: D00320
D00320
| 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 215 215 |
135 | Fentanyl (Low Dose) | 1件: Fentanyl Fentanyl | 1件: D00320
D00320
| 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 215 215 |
136 | Fentanyl (Low Dose) + Dexmedetomidine | 2件: Dexmedetomidine Dexmedetomidine, Fentanyl | 2件: D00320
D00320
,
D00514
| 4件: ADRA2A ADRA2A, ADRA2B, ADRA2C, OPRM1 💬 | 4件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 215 215 |
137 | Fentanyl transdermal patch | 1件: Fentanyl Fentanyl | 1件: D00320
D00320
| 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 |
138 | Feraheme | 1件: Ferumoxytol Ferumoxytol | 1件: D04177
D04177
| - | - | 1件: 13 13 |
139 | Ferinject | - | - | - | - | 2件: 86 86, 299 |
140 | Ferinject or CosmoFer | - | - | - | - | 1件: 86 86 |
141 | Fermented oyster extract | 1件: Oyster Oyster | - | - | - | 1件: 84 84 |
142 | Ferric Carboxy Maltose | 1件: Maltose Maltose | 1件: D00044
D00044
| - | - | 1件: 96 96 |
143 | FERRIC CARBOXYMALTOSE | 1件: Ferric carboxymaltose Ferric carboxymaltose | 1件: D08920
D08920
| - | - | 4件: 86 86, 96, 97, 299 |
144 | Ferric Maltol | 1件: Ferric maltol Ferric maltol | 1件: D10833
D10833
| - | - | 1件: 96 96 |
145 | Ferricarboxymaltose | - | - | - | - | 1件: 86 86 |
146 | Ferriprox | 1件: Deferiprone Deferiprone | 1件: D07416
D07416
| - | - | 2件: 6 6, 120 |
147 | Ferriprox 500 mg | 1件: Deferiprone Deferiprone | 1件: D07416
D07416
| - | - | 1件: 6 6 |
148 | FERRIPROX*100CPR RIV 500MG | 1件: Deferiprone Deferiprone | 1件: D07416
D07416
| - | - | 1件: 120 120 |
149 | Ferrograd | - | - | - | - | 1件: 46 46 |
150 | Ferrograd Folic Tablets | - | - | - | - | 1件: 46 46 |
151 | Ferrous sulfate 325mg | 1件: Sulfate ion Sulfate ion | - | - | - | 1件: 299 299 |
152 | Ferrous sulphate | - | - | - | - | 2件: 96 96, 97 |
153 | Ferrous sulphate 200mg oral tablet | - | - | - | - | 1件: 227 227 |
154 | Ferrprox (Deferiprone) | 1件: Deferiprone Deferiprone | 1件: D07416
D07416
| - | - | 1件: 6 6 |
155 | Ferulic acid | 1件: Ferulic acid Ferulic acid | - | - | - | 1件: 127 127 |
156 | Ferumoxytol | 1件: Ferumoxytol Ferumoxytol | 1件: D04177
D04177
| - | - | 1件: 13 13 |
157 | Fesoterodine | 1件: Fesoterodine Fesoterodine | 1件: D07226
D07226
| 2件: CHRM2 CHRM2, CHRM3 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 |
158 | Fetal porcine cells, Neurocell-PD | - | - | - | - | 1件: 6 6 |
159 | Fexinidazole | 1件: Fexinidazole Fexinidazole | 1件: D11252
D11252
| - | - | 1件: 65 65 |
160 | Fexofenadine | 1件: Fexofenadine Fexofenadine | 1件: D07958
D07958
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 46 |
161 | FFP104 | - | - | - | - | 2件: 93 93, 96 |
162 | FG-3019 | - | - | - | - | 3件: 85 85, 113, 222 |
163 | FG-3019 10mg/mL in 10 mL vials | - | - | - | - | 1件: 85 85 |
164 | Fibrate treatment | - | - | - | - | 1件: 160 160 |
165 | Fibrin | 1件: Fibrin Fibrin | - | - | - | 1件: 279 279 |
166 | Fibrinogen | 1件: Fibrinogen human Fibrinogen human | - | - | - | 2件: 14 14, 65 |
167 | Fibrinogen (coagulation factorI) | 1件: Fibrinogen human Fibrinogen human | - | - | - | 1件: 65 65 |
168 | Fibrinogen concentrate | 1件: Fibrinogen human Fibrinogen human | - | - | - | 1件: 14 14 |
169 | Fibrinogen Concentrate from Human Plasma | 1件: Fibrinogen human Fibrinogen human | - | - | - | 1件: 65 65 |
170 | Fibroblasts | - | - | - | - | 1件: 36 36 |
171 | Fibrogammin P | - | - | - | - | 1件: 288 288 |
172 | Fibrogammin® 1250 | - | - | - | - | 1件: 51 51 |
173 | Fibrogammin® P | - | - | - | - | 1件: 288 288 |
174 | Fibrogammin®P | - | - | - | - | 1件: 288 288 |
175 | Fibrogammin®P, coagulation factor XIII concentrate (Human) | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 51 51 |
176 | Fibrovein | - | - | - | - | 1件: 279 279 |
177 | Fibrovein 3% | - | - | - | - | 1件: 279 279 |
178 | Fig | 1件: Fig Fig | - | - | - | 1件: 2 2 |
179 | Filamentous haemagglutinin | 1件: Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) | - | - | - | 1件: 46 46 |
180 | Filamentous haemagglutinin adsorbed | 1件: Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) | - | - | - | 1件: 46 46 |
181 | FILGOTINIB | 1件: Filgotinib Filgotinib | 1件: D10871
D10871
| 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 6件: 46 46, 53, 96, 97, 222, 271 |
182 | Filgotinib 200mg/day | 1件: Filgotinib Filgotinib | 1件: D10871
D10871
| 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
183 | Filgrastim | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 28件: 2 2, 6, 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 |
184 | Filgrastim (G-CSF) | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 331 331 |
185 | Filgrastim Hexal | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 |
186 | Filgrastim, Alemtuzumab | 2件: Alemtuzumab Alemtuzumab, Filgrastim | 2件: D02802
D02802
,
D03235
| 2件: CD52 CD52, CSF3R 💬 | - | 1件: 65 65 |
187 | Film-coated tablet | - | - | - | - | 1件: 97 97 |
188 | Finamine tablets | - | - | - | - | 1件: 6 6 |
189 | Finasteride | 1件: Finasteride Finasteride | 1件: D00321
D00321
| 1件: SRD5A2 SRD5A2 💬 | 3件: Metabolic pathways Metabolic pathways, Prostate cancer, Steroid hormone biosynthesis 💬 | 1件: 6 6 |
190 | Finely ground flaxseed powder | 1件: Flax seed Flax seed | - | - | - | 1件: 299 299 |
191 | Fingolimob | - | - | - | - | 1件: 13 13 |
192 | Fingolimob (FTY) | - | - | - | - | 1件: 13 13 |
193 | FINGOLIMOD | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 3件: 13 13, 14, 156 |
194 | Fingolimod (FTY720) | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 156 |
195 | Fingolimod 0.5 mg | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
196 | Fingolimod 0.5mg | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
197 | Fingolimod 1.25 mg | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
198 | FINGOLIMOD HYDROCHLORIDE | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 14 |
199 | Fingolimodi | - | - | - | - | 1件: 13 13 |
200 | Fingolmod | - | - | - | - | 1件: 13 13 |
201 | Fipamezole | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 |
202 | Fipamezole hydrochloride | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 |
203 | Fipamezole hydrochloride 30 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 |
204 | Fipamezole hydrochloride 60 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 |
205 | Fipamezole hydrochloride 90 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 |
206 | Fipamezole ODT | 1件: Fipamezole Fipamezole | - | - | - | 1件: 6 6 |
207 | Fipamezole ODT Cohort 2 | 1件: Fipamezole Fipamezole | - | - | - | 1件: 6 6 |
208 | Firategrast | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
209 | Firategrast (USAN approved name) | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
210 | Firategrast 150 mg | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
211 | Firategrast 300 mg | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
212 | Firategrast gastro-retentive solution | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
213 | Firategrast immediate release tablet | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
214 | Firategrast modified release tablet | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
215 | Firdapse | 1件: Amifampridine Amifampridine | 1件: D10228
D10228
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 3 3, 11 |
216 | FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE | 1件: Amifampridine Amifampridine | 1件: D10228
D10228
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 3 3, 11 |
217 | First line DMT | - | - | - | - | 1件: 13 13 |
218 | Fisetin | 1件: Fisetin Fisetin | - | - | - | 1件: 65 65 |
219 | Fish Oil | 1件: Fish oil Fish oil | - | - | - | 8件: 13 13, 46, 49, 66, 96, 260, 294, 299 |
220 | Fish oil concentrate | 1件: Fish oil Fish oil | - | - | - | 1件: 13 13 |
221 | Fish oil supplement | 1件: Fish oil Fish oil | - | - | - | 1件: 46 46 |
222 | Fish oil, gamma-linolenic acid | 3件: Fish oil Fish oil, Gamolenic acid, alpha-Linolenic acid | 1件: D07213
D07213
| - | - | 1件: 46 46 |
223 | FISH OIL, RICH IN OMEGA-3-ACIDS | 2件: Fish oil Fish oil, Omega-3 fatty acids | - | - | - | 1件: 13 13 |
224 | FISH OIL,RICH IN OMEGA 3 ACIDS | 1件: Fish oil Fish oil | - | - | - | 1件: 13 13 |
225 | FITC-Adalimumab | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 |
226 | Fixed dose combination Ciprofloxacin/Celecoxib | 2件: Celecoxib Celecoxib, Ciprofloxacin | 2件: D00186
D00186
,
D00567
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 2 2 |
227 | FK-506 | - | - | - | - | 1件: 60 60 |
228 | FK506 | - | - | - | - | 1件: 222 222 |
229 | FK506 level 2-3 ng/ml | - | - | - | - | 1件: 86 86 |
230 | FK506 level 3-5 ng/ml | - | - | - | - | 1件: 86 86 |
231 | FK506 level < 2 ng/ml | - | - | - | - | 1件: 86 86 |
232 | FKB327 | - | - | - | - | 1件: 46 46 |
233 | FKB327 AI | - | - | - | - | 1件: 46 46 |
234 | FKB327 PFS | - | - | - | - | 1件: 46 46 |
235 | Flagyl | 1件: Metronidazole Metronidazole | 1件: D00409
D00409
| - | - | 2件: 96 96, 97 |
236 | Flavocoxid | - | - | - | - | 1件: 113 113 |
237 | Flavoxate | 1件: Flavoxate Flavoxate | 1件: D07961
D07961
| 16件: PDE10A PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE8B 💬 | 18件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 |
238 | Flaxseed | 1件: Flax seed Flax seed | - | - | - | 2件: 97 97, 299 |
239 | Flaxseed lignan-enriched complex (FLC) | 1件: Flax seed Flax seed | - | - | - | 1件: 97 97 |
240 | FLEBOGAMMA 5% | - | - | - | - | 1件: 15 15 |
241 | Flebogamma 5% DIF | - | - | - | - | 1件: 65 65 |
242 | Flecainide | 1件: Flecainide Flecainide | 1件: D07962
D07962
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 6 6 |
243 | FLECAINIDE ACETATE | 2件: Acetate Acetate, Flecainide | 1件: D07962
D07962
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 6 6 |
244 | Flecainidum | 1件: Flecainide Flecainide | 1件: D07962
D07962
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 6 6 |
245 | Flixabi | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 |
246 | Flolan | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
247 | FLOLAN injection with currently marketed diluent | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
248 | FLOLAN injection with reformulated diluent | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
249 | FLOLAN TM and Glycine Diluent | 2件: Epoprostenol Epoprostenol, Glycine | 2件: D00011
D00011
,
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
250 | Flolan® | 1件: Epoprostenol Epoprostenol | 1件: D00106
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
251 | FLOLAN™ and Glycine Diluent | 2件: Epoprostenol Epoprostenol, Glycine | 2件: D00011
D00011
,
D00106
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
252 | FLORBETABEN (18F) | 1件: Florbetaben (18F) Florbetaben (18F) | - | - | - | 1件: 6 6 |
253 | Florbetapir (18F) | 1件: Florbetapir (18F) Florbetapir (18F) | - | - | - | 1件: 127 127 |
254 | Florbetapir 18F | - | - | - | - | 1件: 127 127 |
255 | Florbetapir 18F Injection | - | - | - | - | 1件: 127 127 |
256 | Florbetapir F 18 | - | - | - | - | 1件: 6 6 |
257 | Florence 30 µg/mL | - | - | - | - | 1件: 98 98 |
258 | Florence 60 µg/mL | - | - | - | - | 1件: 98 98 |
259 | Florence 90 µg/mL | - | - | - | - | 1件: 98 98 |
260 | Flortaucipir | 1件: Flortaucipir Flortaucipir | 1件: D11210
D11210
| 1件: MAPT MAPT 💬 | 4件: Alzheimer disease Alzheimer disease, MAPK signaling pathway, Parkinson disease, Pathways of neurodegeneration - multiple diseases 💬 | 3件: 5 5, 7, 127 |
261 | Flortaucipir F18 | 1件: Flortaucipir Flortaucipir | 1件: D11210
D11210
| 1件: MAPT MAPT 💬 | 4件: Alzheimer disease Alzheimer disease, MAPK signaling pathway, Parkinson disease, Pathways of neurodegeneration - multiple diseases 💬 | 3件: 5 5, 7, 127 |
262 | Floseal | - | - | - | - | 1件: 227 227 |
263 | Flovent | - | - | - | - | 1件: 98 98 |
264 | FLT190 | - | - | - | - | 1件: 19 19 |
265 | FLT201 | - | - | - | - | 1件: 19 19 |
266 | Flu-ATG | - | - | - | - | 1件: 60 60 |
267 | Flucinolone acetonide | - | - | - | - | 1件: 56 56 |
268 | FLUCLOXACILLIN | 1件: Flucloxacillin Flucloxacillin | 1件: D04196
D04196
| - | - | 1件: 299 299 |
269 | Flucloxacillin 250mg/5ml Sugar-Free Powder for Oral Solution | 1件: Flucloxacillin Flucloxacillin | 1件: D04196
D04196
| - | - | 1件: 299 299 |
270 | FLUCLOXACILLIN SODIUM | 1件: Flucloxacillin Flucloxacillin | 1件: D04196
D04196
| - | - | 1件: 299 299 |
271 | Flucloxicillin | - | - | - | - | 1件: 299 299 |
272 | FLUCONAZOLE | 1件: Fluconazole Fluconazole | 1件: D00322
D00322
| - | - | 2件: 96 96, 225 |
273 | FLUDARA | 1件: Fludarabine Fludarabine | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
274 | Fludarabina | 1件: Fludarabine Fludarabine | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 19 19, 65 |
275 | Fludarabina Accord | 1件: Fludarabine Fludarabine | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 |
276 | FLUDARABINA ACCORD - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 5 FLACONCINI IN VETRO DA 2 ML | 1件: Fludarabine Fludarabine | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 19 19 |
277 | FLUDARABINA FOSFATO | 1件: Fludarabine Fludarabine | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 19 19 |
278 | FLUDARABINA TEVA - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 1 FLACONCINO DI VETRO DA 2 ML | 1件: Fludarabine Fludarabine | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 |
279 | Fludarabine | 1件: Fludarabine Fludarabine | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 19件: 11 11, 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326 |
280 | Fludarabine (FLU) | 1件: Fludarabine Fludarabine | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 60 60, 285 |
281 | Fludarabine monophosphate | 1件: Fludarabine Fludarabine | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 3件: 65 65, 284, 326 |
282 | Fludarabine phosphate | 2件: Fludarabine Fludarabine, Phosphate ion | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 12件: 28 28, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286 |
283 | Fludarabine phosphate 30 mg | 2件: Fludarabine Fludarabine, Phosphate ion | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 |
284 | Fludarabine phosphate 40 mg | 2件: Fludarabine Fludarabine, Phosphate ion | 1件: D07966
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 |
285 | Fludarabine, Busulfan, Thymoglobulin | 3件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit), Busulfan, Fludarabine | 2件: D00248
D00248
,
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 |
286 | Fludarabine, Cyclophosphamide | 2件: Cyclophosphamide Cyclophosphamide, Fludarabine | 3件: D00287
D00287
,
D07760
,
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 60 60 |
287 | Fludarabine, Melphalan, Thiotepa | 3件: Fludarabine Fludarabine, Melphalan, Thiotepa | 3件: D00369
D00369
,
D00583
,
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 |
288 | Fludarabine/ melphalan | 2件: Fludarabine Fludarabine, Melphalan | 2件: D00369
D00369
,
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 60 60 |
289 | Fludarabine/busulfan | 2件: Busulfan Busulfan, Fludarabine | 2件: D00248
D00248
,
D07966
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 60 60 |
290 | Fludeoxyglucose | 1件: Fludeoxyglucose Fludeoxyglucose | 1件: D01843
D01843
| - | - | 3件: 84 84, 85, 88 |
291 | Fludrocortisone | 1件: Fludrocortisone Fludrocortisone | 1件: D07967
D07967
| 1件: NR3C2 NR3C2 💬 | 1件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption 💬 | 3件: 6 6, 17, 81 |
292 | Fluimucil | - | - | - | - | 4件: 85 85, 94, 193, 298 |
293 | Fluimucil (acetylcysteine) | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 1件: 193 193 |
294 | FLUIMUCIL*20CPR EFF 600MG | - | - | - | - | 2件: 94 94, 298 |
295 | Fluimucil® 600 mg effervescent tablets | - | - | - | - | 1件: 85 85 |
296 | Flumazenil | 1件: Flumazenil Flumazenil | 1件: D00697
D00697
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 5件: 6 6, 13, 17, 18, 206 |
297 | FluMist | 1件: Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen | - | - | - | 1件: 299 299 |
298 | Flumist® | 1件: Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen | - | - | - | 1件: 299 299 |
299 | Fluocinolone | 1件: Fluocinolone Fluocinolone | - | - | - | 1件: 90 90 |
300 | Fluocinolone Acetonide | 2件: Fluocinolone Fluocinolone, Fluocinolone acetonide | 1件: D01825
D01825
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 90 90 |
301 | Fluorescein | 1件: Fluorescein Fluorescein | 1件: D01261
D01261
| - | - | 2件: 22 22, 97 |
302 | Fluorescence in situ hybridization | - | - | - | - | 1件: 285 285 |
303 | Fluorescite | - | - | - | - | 1件: 215 215 |
304 | FLUORINE (18F) FLUDEOXYGLUCOSE | 1件: Fludeoxyglucose Fludeoxyglucose | 1件: D01843
D01843
| - | - | 2件: 84 84, 85 |
305 | FLUORINE-18 | 1件: Fluorine F-18 Fluorine F-18 | 1件: D05860
D05860
| - | - | 1件: 41 41 |
306 | Fluorodeoxyglucose | - | - | - | - | 1件: 84 84 |
307 | Fluoxetin | 1件: Fluoxetine Fluoxetine | 1件: D00326
D00326
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 3件: 13 13, 179, 206 |
308 | Fluoxetin Hexal | 1件: Fluoxetine Fluoxetine | 1件: D00326
D00326
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 13 13 |
309 | FLUOXETINE | 1件: Fluoxetine Fluoxetine | 1件: D00326
D00326
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 4件: 13 13, 17, 78, 86 |
310 | FLUOXETINE HYDROCHLORIDE | 1件: Fluoxetine Fluoxetine | 1件: D00326
D00326
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 13 13 |
311 | Fluoxétine | 1件: Fluoxetine Fluoxetine | 1件: D00326
D00326
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 17 17 |
312 | Flupentixol | 1件: Flupentixol Flupentixol | 1件: D01044
D01044
| 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 97 97 |
313 | Flupirtin | - | - | - | - | 1件: 13 13 |
314 | Flupirtine | 1件: Flupirtine Flupirtine | 1件: D07978
D07978
| - | - | 1件: 13 13 |
315 | Flupirtinmaleat | - | - | - | - | 1件: 13 13 |
316 | FLURBIPROFEN | 1件: Flurbiprofen Flurbiprofen | 1件: D00330
D00330
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 3件: 13 13, 21, 46 |
317 | Flutamide | 1件: Flutamide Flutamide | 1件: D00586
D00586
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 81 81 |
318 | Flutemetamol | 1件: Flutemetamol (18F) Flutemetamol (18F) | - | - | - | 4件: 5 5, 6, 7, 127 |
319 | Fluticasone | 1件: Fluticasone Fluticasone | 1件: D07981
D07981
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 98 98, 228, 299 |
320 | Fluticasone MDI | 1件: Fluticasone Fluticasone | 1件: D07981
D07981
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
321 | FLUTICASONE PROPIONATE | 1件: Fluticasone propionate Fluticasone propionate | 1件: D01708
D01708
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 98 98, 228 |
322 | Fluticasone Propionate, USP | 1件: Fluticasone propionate Fluticasone propionate | 1件: D01708
D01708
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
323 | Fluvastatin | 1件: Fluvastatin Fluvastatin | 1件: D07983
D07983
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 3件: 79 79, 218, 222 |
324 | Fluzone | 1件: Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) | - | - | - | 2件: 21 21, 49 |
325 | Fluzone® | 1件: Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) | - | - | - | 1件: 21 21 |
326 | FLX-787-ODT | - | - | - | - | 1件: 2 2 |
327 | FLX-787-ODT (orally disintegrating tablet) | - | - | - | - | 1件: 10 10 |
328 | FLX-787-ODT (orally disintigrating tablet) | - | - | - | - | 1件: 2 2 |
329 | FMP-30 | - | - | - | - | 1件: 53 53 |
330 | FMP30 Donor Stool | - | - | - | - | 1件: 13 13 |
331 | FMT | - | - | - | - | 2件: 96 96, 97 |
332 | FMT enema | - | - | - | - | 1件: 97 97 |
333 | FMT infusions | - | - | - | - | 1件: 97 97 |
334 | FMT oral | - | - | - | - | 1件: 97 97 |
335 | Focetria | - | - | - | - | 1件: 46 46 |
336 | Focetria (Monovalent MF59-Adjuvanted vaccine) | - | - | - | - | 3件: 46 46, 49, 271 |
337 | Folate | 1件: Folic acid Folic acid | 1件: D00070
D00070
| - | - | 3件: 41 41, 46, 49 |
338 | FolateScan (Technetium Tc 99mEC20) | - | - | - | - | 4件: 13 13, 46, 49, 96 |
339 | Folic (or folinic) acid | - | - | - | - | 1件: 46 46 |
340 | Folic acid | 1件: Folic acid Folic acid | 1件: D00070
D00070
| - | - | 5件: 6 6, 46, 49, 84, 296 |
341 | Folic acid (non-investigational product) | 1件: Folic acid Folic acid | 1件: D00070
D00070
| - | - | 1件: 46 46 |
342 | Folic acid or folate | 1件: Folic acid Folic acid | 1件: D00070
D00070
| - | - | 1件: 46 46 |
343 | Folic Acid, Vitamin B6, Vitamin B12 | 3件: Cyanocobalamin Cyanocobalamin, Folic acid, Pyridoxine | 6件: D00070
D00070
,
D00166
,
D03615
,
D03616
,
D03617
,
D08454
| - | - | 1件: 6 6 |
344 | Folic/folinic acid | 1件: Leucovorin Leucovorin | 2件: D07986
D07986
,
D07987
| - | - | 2件: 46 46, 107 |
345 | Foliglurax | 1件: Foliglurax Foliglurax | - | - | - | 1件: 6 6 |
346 | Foliglurax 10 mg (treatment A) | 1件: Foliglurax Foliglurax | - | - | - | 1件: 6 6 |
347 | Foliglurax 30 mg (treatment B) | 1件: Foliglurax Foliglurax | - | - | - | 1件: 6 6 |
348 | Folimet | - | - | - | - | 1件: 46 46 |
349 | Folinic acid | 1件: Leucovorin Leucovorin | 2件: D07986
D07986
,
D07987
| - | - | 3件: 46 46, 107, 320 |
350 | Follow-up study of the treated cohort | - | - | - | - | 1件: 193 193 |
351 | Fontolizumab | 1件: Fontolizumab Fontolizumab | 1件: D04242
D04242
| 1件: IFNG IFNG 💬 | 32件: African trypanosomiasis African trypanosomiasis, Allograft rejection, Amoebiasis, Antigen processing and presentation, Chagas disease, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hepatitis C, Herpes simplex virus 1 infection, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Leishmaniasis, Malaria, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Proteasome, Rheumatoid arthritis, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 46 46 |
352 | Foralumab | 1件: Foralumab Foralumab | - | - | - | 2件: 13 13, 96 |
353 | Fordadistrogene movaparvovec | 1件: Fordadistrogene movaparvovec Fordadistrogene movaparvovec | - | - | - | 1件: 113 113 |
354 | Forigerimod | 1件: Forigerimod Forigerimod | 1件: D09904
D09904
| - | - | 1件: 49 49 |
355 | FORLAX 4 g, poudre pour solution buvable en sachet | - | - | - | - | 1件: 299 299 |
356 | Formistin | - | - | - | - | 1件: 13 13 |
357 | FORMISTIN - 10 MG COMPRESSE RIVESTITE CON FILM 20 COMPRESSE | - | - | - | - | 1件: 13 13 |
358 | Formistin 10 mg | - | - | - | - | 1件: 13 13 |
359 | Formoterol | 1件: Formoterol Formoterol | 1件: D07990
D07990
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 85 85, 228, 299 |
360 | Formoterol fumarate dihydrate | 1件: Formoterol Formoterol | 1件: D07990
D07990
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 |
361 | Formoterol/Budesonide | 2件: Budesonide Budesonide, Formoterol | 2件: D00246
D00246
,
D07990
| 2件: ADRB2 ADRB2, NR3C1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 |
362 | Formulation A | - | - | - | - | 1件: 13 13 |
363 | Formulation B | - | - | - | - | 1件: 13 13 |
364 | Formulation C | - | - | - | - | 1件: 13 13 |
365 | Formulation D | - | - | - | - | 1件: 13 13 |
366 | Forsteo | 1件: Teriparatide Teriparatide | 1件: D06078
D06078
| 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 3件: 70 70, 235, 274 |
367 | FORSTEO-R | 1件: Teriparatide Teriparatide | 1件: D06078
D06078
| 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 |
368 | FORTECORTIN | - | - | - | - | 2件: 28 28, 65 |
369 | Fortecortin Inject 40 mg Amp. | - | - | - | - | 1件: 65 65 |
370 | Forteo | 1件: Teriparatide Teriparatide | 1件: D06078
D06078
| 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 70 70 |
371 | Fortiral | - | - | - | - | 1件: 6 6 |
372 | Fortum | - | - | - | - | 1件: 299 299 |
373 | Forxiga | 1件: Dapagliflozin Dapagliflozin | 1件: D08897
D08897
| 1件: SLC5A2 SLC5A2 💬 | - | 2件: 86 86, 88 |
374 | Forxiga (dapagliflozin) | 1件: Dapagliflozin Dapagliflozin | 1件: D08897
D08897
| 1件: SLC5A2 SLC5A2 💬 | - | 2件: 86 86, 88 |
375 | FOS | - | - | - | - | 2件: 66 66, 96 |
376 | Foscarbidopa | 1件: Foscarbidopa Foscarbidopa | 1件: D12057
D12057
| - | - | 1件: 6 6 |
377 | Foscarbidopa and Foslevodopa | 2件: Foscarbidopa Foscarbidopa, Foslevodopa | 2件: D11839
D11839
,
D12057
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
378 | Foscarnet | 1件: Foscarnet Foscarnet | - | - | - | 1件: 60 60 |
379 | FosD | - | - | - | - | 1件: 46 46 |
380 | Fosfamatinib Disodium | - | - | - | - | 1件: 46 46 |
381 | Fosfato sodico de dexametasona | 1件: Dexamethasone Dexamethasone | 1件: D00292
D00292
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 |
382 | Fosfomycin | 1件: Fosfomycin Fosfomycin | 1件: D04253
D04253
| - | - | 2件: 96 96, 97 |
383 | FOSFOMYCIN DISODIUM | 1件: Fosfomycin Fosfomycin | 1件: D04253
D04253
| - | - | 1件: 97 97 |
384 | Foslevodopa | 1件: Foslevodopa Foslevodopa | 1件: D11839
D11839
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
385 | Fosmetpantotenate | - | - | - | - | 1件: 120 120 |
386 | Fosmetpantotenate (RE-024) | - | - | - | - | 1件: 120 120 |
387 | FOSMETPANTOTENATE DRUG SUBSTANCE | - | - | - | - | 1件: 120 120 |
388 | Fosmetpantotenato | - | - | - | - | 1件: 120 120 |
389 | Fospropofol | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 |
390 | Fospropofol (Lusedra®) 10 | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 |
391 | Fospropofol (Lusedra®) 12 | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 |
392 | Fospropofol (Lusedra®) 6.5 | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 |
393 | Fostair | - | - | - | - | 1件: 85 85 |
394 | Fostamatinib | 1件: Fostamatinib Fostamatinib | 1件: D09347
D09347
| 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 4件: 46 46, 49, 61, 66 |
395 | Fostamatinib 100 mg | 1件: Fostamatinib Fostamatinib | 1件: D09347
D09347
| 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 |
396 | Fostamatinib 100 mg tablet | 1件: Fostamatinib Fostamatinib | 1件: D09347
D09347
| 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 |
397 | Fostamatinib 150 mg | 1件: Fostamatinib Fostamatinib | 1件: D09347
D09347
| 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 |
398 | Fostamatinib 150 mg bid | 1件: Fostamatinib Fostamatinib | 1件: D09347
D09347
| 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 61 61 |
399 | Fostamatinib 150 mg tablet | 1件: Fostamatinib Fostamatinib | 1件: D09347
D09347
| 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 |
400 | Fostamatinib 50 mg blue film-coated tablet | 1件: Fostamatinib Fostamatinib | 1件: D09347
D09347
| 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
401 | Fostamatinib Disodium | 1件: Fostamatinib Fostamatinib | 1件: D09347
D09347
| 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 3件: 46 46, 61, 66 |
402 | Fostamatinib Disodium (R935788) | 1件: Fostamatinib Fostamatinib | 1件: D09347
D09347
| 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 49 |
403 | Fostamatinib Disodium tablet 100 mg | 1件: Fostamatinib Fostamatinib | 1件: D09347
D09347
| 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 |
404 | Fostamatinib Disodium tablet 150 mg | 1件: Fostamatinib Fostamatinib | 1件: D09347
D09347
| 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 |
405 | FP-110 | - | - | - | - | 1件: 97 97 |
406 | FP-CYA-050 | - | - | - | - | 1件: 97 97 |
407 | FP-CYA-053 | - | - | - | - | 1件: 97 97 |
408 | FPA008 | - | - | - | - | 1件: 46 46 |
409 | FPF 300 (thalidomide) | 1件: Thalidomide Thalidomide | 1件: D00754
D00754
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 16 16 |
410 | FPF1011 | - | - | - | - | 1件: 263 263 |
411 | FPF1100NW | - | - | - | - | 1件: 6 6 |
412 | FPFS-1169 | - | - | - | - | 1件: 6 6 |
413 | FPI-2620 | - | - | - | - | 1件: 127 127 |
414 | FR104 | - | - | - | - | 1件: 46 46 |
415 | Fragmin | 1件: Dalteparin Dalteparin | - | - | - | 1件: 222 222 |
416 | Frameshift Array blood sample test | - | - | - | - | 1件: 34 34 |
417 | Free amino acids intake | 1件: Amino acids Amino acids | - | - | - | 1件: 240 240 |
418 | Freeze-dried black raspberry powder | 1件: Raspberry Raspberry | 1件: D09179
D09179
| - | - | 1件: 97 97 |
419 | Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 43, 45 |
420 | Fremanezumab | 1件: Fremanezumab Fremanezumab | 1件: D11055
D11055
| 1件: CALCA CALCA 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction 💬 | 2件: 124 124, 226 |
421 | Fresenius-Kabi) | - | - | - | - | 1件: 46 46 |
422 | Fresh Frozen Plasma | - | - | - | - | 1件: 5 5 |
423 | Fresolimumab | 1件: Fresolimumab Fresolimumab | 1件: D09620
D09620
| 3件: TGFB1 TGFB1, TGFB2, TGFB3 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Amoebiasis, Cell cycle, Cellular senescence, Chagas disease, Chronic myeloid leukemia, Colorectal cancer, Cytokine-cytokine receptor interaction, Diabetic cardiomyopathy, Dilated cardiomyopathy, FoxO signaling pathway, Gastric cancer, Hepatitis B, Hepatocellular carcinoma, Hippo signaling pathway, Human T-cell leukemia virus 1 infection, Hypertrophic cardiomyopathy, Inflammatory bowel disease, Intestinal immune network for IgA production, Leishmaniasis, MAPK signaling pathway, Malaria, MicroRNAs in cancer, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, TGF-beta signaling pathway, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬 | 2件: 51 51, 222 |
424 | Frisium | - | - | - | - | 1件: 140 140 |
425 | FRISIUM*30CPS 10MG | - | - | - | - | 1件: 140 140 |
426 | FRM-0334 | - | - | - | - | 1件: 127 127 |
427 | From August 2020 'no additional treatment' | - | - | - | - | 1件: 51 51 |
428 | Frondanol | - | - | - | - | 1件: 97 97 |
429 | Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the a-L-iduronidase cDNA, in their final formulation medium. | - | - | - | - | 1件: 19 19 |
430 | FSME-IMMUN | - | - | - | - | 1件: 46 46 |
431 | FT011 | - | - | - | - | 1件: 51 51 |
432 | FT011 100 mg | - | - | - | - | 1件: 51 51 |
433 | FT011 200 mg | - | - | - | - | 1件: 51 51 |
434 | FTI, AZLI | - | - | - | - | 1件: 299 299 |
435 | FTX-1821 | - | - | - | - | 1件: 113 113 |
436 | FTY720 | - | - | - | - | 2件: 13 13, 14 |
437 | FTY720D | - | - | - | - | 1件: 13 13 |
438 | FTY720I | - | - | - | - | 1件: 14 14 |
439 | Fucidin | 1件: Fusidic acid Fusidic acid | 1件: D04281
D04281
| - | - | 1件: 299 299 |
440 | Fucidin Tablets | 1件: Fusidic acid Fusidic acid | 1件: D04281
D04281
| - | - | 1件: 299 299 |
441 | Fucose | 1件: Fucose Fucose | - | - | - | 1件: 65 65 |
442 | Fully human anti-interferon gamma monoclonal antibody | 1件: Interferon Gamma Interferon Gamma | - | - | - | 1件: 107 107 |
443 | Fully human IgG1 monoclonal antibody specific for TL1A | - | - | - | - | 2件: 96 96, 97 |
444 | Fully human IgG2 lambda monoclonal antibody | - | - | - | - | 1件: 172 172 |
445 | Fully human monoclonal antibody directed against CXCL10 | - | - | - | - | 1件: 93 93 |
446 | Fully humanised, recombinant monoclonal antibody (IgG1) | - | - | - | - | 1件: 96 96 |
447 | Fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody | - | - | - | - | 1件: 13 13 |
448 | Fultium-D3 800IU capsules | - | - | - | - | 1件: 274 274 |
449 | Fulvestrant | 1件: Fulvestrant Fulvestrant | 1件: D01161
D01161
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 86 86 |
450 | Fumaderm | - | - | - | - | 1件: 49 49 |
451 | Fumaderm® | - | - | - | - | 1件: 49 49 |
452 | Fumaderm® initial | - | - | - | - | 1件: 49 49 |
453 | Fumaric acid | 1件: Fumaric acid Fumaric acid | 1件: D02308
D02308
| - | - | 1件: 13 13 |
454 | FURESTEM-RA Inj | - | - | - | - | 1件: 46 46 |
455 | FURESTEM-RA Inj. | - | - | - | - | 1件: 46 46 |
456 | Furosemide | 1件: Furosemide Furosemide | 1件: D00331
D00331
| 1件: SLC12A2 SLC12A2 💬 | 3件: Pancreatic secretion Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬 | 2件: 6 6, 86 |
457 | Furosemide Injection | 1件: Furosemide Furosemide | 1件: D00331
D00331
| 1件: SLC12A2 SLC12A2 💬 | 3件: Pancreatic secretion Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬 | 1件: 6 6 |
458 | Fusidate | 1件: Fusidic acid Fusidic acid | 1件: D04281
D04281
| - | - | 1件: 299 299 |
459 | FUSIDIC ACID | 1件: Fusidic acid Fusidic acid | 1件: D04281
D04281
| - | - | 1件: 299 299 |
460 | Fusidin | - | - | - | - | 1件: 299 299 |
461 | Fusion | 1件: Iron polymaltose Iron polymaltose | - | - | - | 7件: 11 11, 13, 46, 49, 69, 70, 271 |
462 | Fuzhenghuayu | - | - | - | - | 1件: 93 93 |
463 | Fx-1006A | 1件: Fx-1006A Fx-1006A | - | - | - | 1件: 28 28 |
464 | FX125L | - | - | - | - | 1件: 46 46 |
465 | FXIIa inhibitor monoclonal antibody | - | - | - | - | 1件: 85 85 |
466 | FXIII Concentrate (Human) | - | - | - | - | 1件: 288 288 |
467 | FXIII Concentrate (Human) (FXIII) | - | - | - | - | 1件: 288 288 |
468 | Fycompa | 1件: Perampanel Perampanel | 1件: D08964
D08964
| 4件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4 💬 | 16件: Amphetamine addiction Amphetamine addiction, Amyotrophic lateral sclerosis, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 2件: 2 2, 144 |